Earnings Call Intelligence Subscribe
Home › Call Sheets › DHR › Q3'26
Call sheet · Q3'26

Danaher (DHR)

Q3'26 earnings call · held October 21, 2026 · compared with the Q2'26 call · management-credibility review
10/12
Disclosure score
2 medium, 1 low flags
Financial quality
Bottom line
Danaher improved core growth excluding respiratory testing to 5.5%, while total core growth remained 3%. Adjusted EPS guidance increased, and cash generation was solid. The key tests are recurring margin after refunds, respiratory demand against the revised $1.5B assumption and conversion of bioprocessing orders. The preliminary 2027 framework is a starting point, with formal guidance due in January. Shipments expected in 2027 are not overdue in Q3 2026.

The 30-second version

  • Underlying growth improved, but keep the scopes separate
  • The 2027 framework is a starting point
  • Margin improved, with one-time help

What changed this quarter

MetricQ2'26Q3'26Change
Core revenue growth, ex-respiratory4.5% (150bps accel from Q1)5.5% (100bps accel from Q2)+100bps acceleration
Total core revenue growth3.0% YoY3.0% YoYFlat headline masks underlying acceleration (resp drag offsetting gains)
Sales$6.3B$6.6B+~5% sequential
Adjusted diluted EPS$1.94, +8% YoY$2.11, +11.5% YoYAccelerating EPS growth
Adjusted operating margin27.1%, down 20bps29.0%, up 110bps (incl. tariff refund benefit)Up 190bps sequentially; 110bps YoY expansion includes a modest refund benefit.
Gross margin57.6%58.5%+90bps
Free cash flow (qtr / YTD / conversion)$1.3B / $2.4B / 124%$1.6B / $4.0B / 128%Conversion improving
Bioprocessing core growthLow single digitsUpper end of mid-single digitsImproved; shipment timing expected in 2027 remains a future test.
Bioprocessing order growthMid-teensMid-teensMid-teens growth maintained.
Life Sciences segment core growth5.5%4.5%-100bps deceleration

Accountability tracked

5 new promises made1 narrative shift flagged5 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full DHR Q3'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.